Viruses mutate, and SARS-CoV-2 is no exception. Emerging mutation surveillance and confirmation
Friday, July 9, 2021
11. Other, 2-hour Integrated Symposium
11c. Other
•
2789
•
1:15 PM
>
3:15 PM
•
Viruses mutate, and SARS-CoV-2 is no exception. Emerging mutation surveillance and confirmation
•
15. Integrated Sessions – 3
11c. Other
Some recent emerging SARS-CoV-2 variants have accumulated significantly more mutations in short periods of time, causing concern around the globe. Scientists predict that these mutant lineages of the SARS-CoV-2 strain will not be the only concerning variants that emerge, caused by continued uncontrolled transmission of SARS-CoV-2 and selective pressures. Whether your lab is interested in the detection of SARS-CoV-2 or if you are looking to verify viral mutations, it can be challenging to consider the best approach. Receive first-hand information from scientific experts on rapid detection of SARS-CoV-2, and confirmation of variants by qPCR and sequencing technologies. Learn about important considerations related to assay design, sample collection and processing, and availability of supply. The final aim of this session is to provide new inputs on gold-standard molecular diagnostic technology and surveillance options for understanding the evolution of viral pathogens such as SARS-CoV-2.
1:15 PM
•
2789-1
•
Welcome and introduction
1:20 PM
•
2789-2
•
Performance characteristics of COVID-19 tests: a comparative study
>
U.
Ulrich
EIGNER (Heidelberg)
1:32 PM
•
2789-3
•
SARS-CoV-2 testing in the community: finding variants in real-time
>
A.
Alan
MCNALLY (Birmingham)
1:52 PM
•
2789-4
•
Designed with virus mutations in mind: SARS-CoV-2 testing and sequencing solutions
>
J.
Jelena
FEENSTRA (Vienna)
2:12 PM
•
2789-5
•
SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
>
M.
Marco
LODDO (Little Chesterford)
2:27 PM
•
2789-6
•
Routine implementation of SARS-CoV-2 NGS analysis at Amsterdam UMC
>
M.
Marcel
JONGES (Amsterdam)
2:40 PM
•
2789-7
•
Panel discussion and live Q&A
3:10 PM
•
2789-8
•
Closing remarks by the Chairs
|